KELUN PHARMA(SZ:002422)2023-04-13 16:00Financial Performance - The total revenue for Sichuan Kelun Pharmaceutical Co., Ltd. in 2022 was reported at 10.5 billion RMB, representing a year-on-year increase of 15%[8]. - The company achieved a net profit of 1.8 billion RMB in 2022, which is a growth of 12% compared to the previous year[8]. - The company's operating revenue for 2022 was ¥18.91 billion, an increase of 9.46% compared to ¥17.28 billion in 2021[15]. - Net profit attributable to shareholders for 2022 reached ¥1.71 billion, reflecting a significant growth of 54.98% from ¥1.10 billion in 2021[15]. - The company reported a net cash flow from operating activities of ¥3.13 billion, which is a 9.85% increase from ¥2.85 billion in 2021[15]. - The company has set a revenue target of 12 billion RMB for 2023, reflecting a growth forecast of 14%[8]. - The company reported a significant increase in sales, with a growth rate exceeding 15 times in the Hubei province during the tenure of the marketing manager[178]. - The company achieved a net profit margin of 18% for 2022, reflecting effective cost management strategies implemented throughout the year[196]. Research and Development - The company has allocated 500 million RMB for R&D in 2023, emphasizing the development of new technologies in pharmaceutical manufacturing[8]. - The company has invested over 10.3 billion yuan in R&D innovation since 2013, with 12 subsidiaries recognized as national high-tech enterprises[27]. - The company launched over 400 drug research projects, including 380 generic and improved innovative drugs, and 33 innovative drugs[50]. - The company is committed to enhancing its R&D capabilities and expanding its market presence through innovative therapies and strategic clinical developments[96][97]. - Research and development expenses increased by 30% to 1.2 billion yuan, reflecting the company's commitment to innovation and new technology[173]. - The company aims to enhance its R&D system to address unmet clinical needs, focusing on differentiated products and cost advantages to support sales growth amid ongoing price pressures in the pharmaceutical sector[142]. Product Development and Market Expansion - The company plans to launch three new products in 2023, focusing on innovative drug delivery systems and biosimilars[8]. - Sichuan Kelun aims to increase its market share in Southeast Asia by 25% over the next two years through strategic partnerships and local collaborations[8]. - The company is focusing on expanding its presence in the oncology and anti-infection markets, with several new products targeting these therapeutic areas[54]. - The company is actively developing new products, with multiple drugs such as Sorafenib and Regorafenib in the production application stage, indicating a strong pipeline for oncology treatments[55]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a revenue contribution of 5% from this region by 2024[173]. - The company plans to expand its market presence in parenteral nutrition products through academic promotion and terminal hospital development in 2023[74]. Risk Management - The company faces various risks including industry policy changes, market risks, environmental risks, R&D innovation risks, and quality control risks[2]. - The company has implemented a comprehensive risk management system to maximize project output value and ensure compliance with quality standards[138]. - Environmental risks are actively managed through comprehensive pollution control measures and emergency response plans, ensuring compliance with environmental regulations[143]. Corporate Governance - The board of directors consists of 8 members, including 3 independent directors, complying with legal regulations and the company's articles of association[152]. - The company respects and maintains the legitimate rights and interests of stakeholders, implementing various management systems to balance interests among shareholders, creditors, customers, suppliers, and employees[154]. - The company has established multiple information disclosure management systems to ensure compliance with relevant laws and regulations, enhancing transparency[156]. - The company has engaged with approximately 125 institutional investors online to discuss R&D, marketing, and capital operations[146]. Strategic Initiatives - The company is exploring potential acquisitions in the biotechnology sector to enhance its product portfolio and market presence[8]. - The company has implemented new strategies to improve operational efficiency, aiming to reduce costs by 8% across its manufacturing processes[173]. - The company aims to leverage its strong product pipeline to enhance revenue streams and improve overall financial performance in the coming years[54]. - The company is committed to enhancing its ESG initiatives, with plans to invest 100 million RMB in sustainability projects by 2025[8]. Shareholder Engagement - The company held its 2021 annual general meeting with a 50.32% investor participation rate on May 5, 2022, and a temporary meeting with 53.08% participation on September 13, 2022[161]. - The company has consistently reported losses on foreign exchange forward contracts, with losses ranging from -46.85 million CNY to -75.08 million CNY across various contracts[116]. Financial Management - The company raised a total of RMB 300,000 million through the issuance of convertible bonds, with a net amount of RMB 2,980,053,990.56 after deducting issuance costs[121]. - The company has not experienced any significant changes in project feasibility during the reporting period[123]. - The company has maintained compliance with the planned use of raised funds and has received clear consent from the supervisory board and independent directors for its financial activities[123].